Terbinafine is generally safe for most people, but oral terbinafine carries real risks that are worth understanding before you start treatment. FDA-approved since 1992, it’s one of the most commonly prescribed antifungal medications for nail and skin infections. The topical form (creams, solutions) is very low-risk since less than 1% absorbs into your body. The oral tablet is where safety questions get more serious, particularly around liver health, taste changes, and drug interactions.
Common Side Effects
The most frequent complaints from people taking oral terbinafine are gastrointestinal: nausea, bloating, and stomach upset. Headaches are also common. These tend to be mild and don’t usually force people to stop treatment.
Taste disturbance is the side effect that catches people off guard. Official reporting puts it at 0.6% to 2.8% of users, but objective testing suggests the real number is significantly higher because many people don’t notice subtle taste changes on their own. Research using quantitative taste testing found that terbinafine depresses the ability to detect sweet, sour, bitter, and salty flavors across different areas of the tongue. The good news: taste typically returns after stopping the medication, though recovery can take weeks to months in some cases.
Liver Risk Is Rare but Real
This is the most important safety concern with oral terbinafine. The drug can cause liver injury, and in rare cases, liver failure. The probability varies depending on the data source. A large analysis of U.S. Veterans Administration records from 1999 to 2021 found hospitalizations for acute liver injury at a rate of about 1 per 25,000 patients exposed. A separate prospective study estimated a higher rate of roughly 1 per 2,600 people treated. The true risk likely falls somewhere in that range.
Less than 1% of patients experience temporary elevations in liver enzymes, which are usually harmless and resolve on their own. The more concerning scenario, where liver damage is severe enough to require stopping treatment, happens in about 0.3% to 0.4% of patients. Your prescriber will typically order blood work to check your liver function before starting treatment and may repeat it during the course, especially if you’re taking the drug for longer than a few weeks.
Oral terbinafine is flatly contraindicated if you have chronic or active liver disease. If you’ve had liver problems in the past, make sure your prescriber knows. Warning signs of liver trouble during treatment include unusual fatigue, dark urine, pale stools, yellowing of the skin or eyes, and persistent nausea or upper abdominal pain.
Drug Interactions to Watch For
Terbinafine is a moderate inhibitor of a liver enzyme called CYP2D6, which your body uses to break down a surprisingly long list of medications. When terbinafine blocks this enzyme, those other drugs can build up to higher-than-expected levels in your blood. This inhibition kicks in within the first few days to three weeks of taking terbinafine and can more than double the blood concentration of affected medications.
This matters most if you take certain antidepressants, antipsychotics, beta-blockers, or cough suppressants containing dextromethorphan. If you’re on any regular medication, your prescriber or pharmacist should check for interactions before you start. Don’t assume an antifungal is too minor to cause problems with your other prescriptions.
Rare but Serious Reactions
Stevens-Johnson syndrome and toxic epidermal necrolysis are severe skin reactions that have been reported with terbinafine. These conditions involve blistering and peeling of the skin and are medical emergencies. They’re extremely rare in the general population (roughly 2 to 7 cases per million people per year across all drug causes), and terbinafine is one of many medications identified as a potential trigger. Blood cell abnormalities have also been reported rarely. If you develop an unexplained rash, fever, or mouth sores while taking terbinafine, contact your prescriber promptly.
Kidney Disease and Dose Adjustments
If your kidney function is significantly reduced, terbinafine clears from your body about 50% more slowly than normal. The drug hasn’t been well studied in people with moderate to severe kidney impairment, so your prescriber may need to adjust your approach or monitor you more closely. The same slower clearance applies to people with liver cirrhosis, though active liver disease is already a contraindication for the oral form.
Pregnancy and Breastfeeding
Oral terbinafine is not recommended during pregnancy. Since nail and skin fungal infections are rarely urgent, treatment can almost always wait.
During breastfeeding, the picture is more nuanced. At standard oral doses, terbinafine does pass into breast milk, but at low levels. An exclusively breastfed infant would receive roughly 3.8% of the mother’s weight-adjusted dose. This is generally considered low, especially for infants older than two months. Still, some guidelines recommend avoiding oral terbinafine while nursing, and monitoring the infant for signs of liver irritation (like jaundice) if treatment is necessary.
Topical terbinafine is considered low risk during breastfeeding since so little is absorbed through the skin. The main precaution is to avoid applying it to or near the nipple area and to keep the infant’s skin away from treated areas.
How It Compares to Other Antifungals
Itraconazole is the main alternative oral antifungal for similar infections. In head-to-head comparisons, the two drugs produce similar rates of mild side effects like stomach upset, headache, and taste changes. Neither drug forced patients to stop treatment due to side effects in comparative trials. The key difference is in their rare risks: terbinafine’s main concern is liver injury, while itraconazole carries additional warnings about heart rhythm problems and heart failure. Both require liver monitoring. For most patients with dermatophyte infections, terbinafine tends to be preferred because of its higher cure rates for nail fungus, with a safety profile that’s broadly comparable.
Topical vs. Oral: A Big Safety Gap
If you’re using terbinafine cream or solution for athlete’s foot or jock itch, the safety profile is dramatically better than the oral form. Less than 1% of the drug reaches your bloodstream through the skin, making liver concerns, drug interactions, and taste changes essentially non-issues. Most of the serious risks discussed above apply only to the oral tablet, which is typically reserved for nail infections and more stubborn skin infections that topical treatment can’t reach.